| Literature DB >> 34394394 |
Lichan Chen1,2, Xiaohong Wu2, Xisui Chen1, Chunjiao Zhou3.
Abstract
BACKGROUND: More than 40% of patients with cancer have reported that chemotherapy-induced nausea and vomiting (CINV) remained the most debilitating side effects of treatment even in the era of new antiemetics.Entities:
Year: 2021 PMID: 34394394 PMCID: PMC8357499 DOI: 10.1155/2021/8868720
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
PICO framework.
| Population | Patients receiving cancer chemotherapy |
| Intervention | Auricular acupressure, auricular acupressure combined with antiemetics |
| Comparison | Antiemetics |
| Outcome | Nausea relief efficiency, nausea frequency, vomiting relief efficiency, vomiting frequency, overall efficiency of CINV, and incidence of adverse reactions |
Example of PubMed search strategy.
| ID | Search strategy | Result |
|---|---|---|
| #1 | Search: (“acupuncture, ear”[mesh]) OR ((((((((((((acupunctures, ear[title/abstract]) OR (auricular acupuncture[title/abstract])) OR (ear acupuncture[title/abstract])) OR (acupuncture, auricular[title/abstract])) OR (auricular acupressure[title/abstract])) OR (auricular pressing[title/abstract])) OR (auricular plaster[title/abstract])) OR (auricul | 1,270 |
| #2 | Search: (“drug therapy”[mesh]) OR ((((((((therapy, drug[title/abstract]) OR (drug therapies[title/abstract])) OR (therapies, drug[title/abstract])) OR (chemotherap | 3,349,312 |
| #3 | Search (((“vomiting”[mesh]) OR emesis[title/abstract]) OR “nausea”[mesh])) | 42,016 |
| #4 | #1 AND #2 AND #3 | 8 |
Basic characteristics of inclusion literature.
| Reference and year | Country | Study design | Participants | Tumor category | Auricular acupoints | Materials | Interventions | Antiemetics | Outcomes |
|---|---|---|---|---|---|---|---|---|---|
| Lou et al., 2011 [ | China | Parallel RCT | 50 | Various cancers | Shenmen, stomach, subcortex, spleen, sympathesis, ear center | Cowherb seeds | AA + antiemetics | Granisetron | (i); (iii); (vi) |
| Liu et al., 2011 [ | China | Parallel RCT | 127 | Lung cancer | Lung, stomach, Shenmen, spleen, diazoma, subcortex, large intestine | Cowherb seeds | AA + antiemetics | Granisetron/ondansetron | (v); (Vi) |
| Chao et al., 2012 [ | Taiwan, China | Crossover placebo RCT | 10 | Na | Shenmen, stomach, cardia, sympathesis, subcortex, | Seeds | AA + antiemetics | Granisetron/ondansetron | (ii); (iv) |
| Jiang et al., 2012 [ | China | Parallel RCT | 85 | Na | Stomach, Shenmen, spleen, sympathesis, large intestine | Cowherb seeds | AA + antiemetics | Granisetron | (iii); (vi) |
| Hong et al., 2014 [ | China | Parallel RCT | 120 | Breast cancer | Stomach, Shenmen, spleen, sympathesis, subcortex | Cowherb seeds | AA | Ondansetron | (i); (iii); (vi) |
| Li et al., 2014 [ | China | Parallel RCT | 91 | Lung cancer | Stomach, Shenmen, sympathesis | Cowherb seeds | AA + antiemetics | Ondansetron + DXM | (v) |
| Hu et al. 2014 [ | China | Parallel RCT | 70 | Various cancers | M: stomach, Shenmen, sympathesis; A: spleen, liver | Cowherb seeds | AA + antiemetics | Tropisetron | (v) |
| Eghbali et al., 2016 [ | Iran | Crossover RCT | 96 | Breast cancer | Point zero, stomach, brainstem, Shenmen, cardia | Seeds | AA + standard medications | Standard medications | (ii); (iv) |
| Peng et al., 2016 [ | China | Parallel RCT | 52 | Cervical/endometrial/ovarian cancer | M: Shenmen, diazoma, stomach, cardia, occiput, subcortex, esophagus; A: sympathesis, spleen, liver | Cowherb seeds | AA + antiemetics | Ondansetron + DXM | (i); (iii); (iv); (vi) |
| Wei et al., 2016 [ | China | Parallel RCT | 90 | Na | M: stomach, Shenmen, spleen; A: liver | Cowherb seeds | AA + antiemetics | Azasetron | (v) |
| Guo et al., 2017 [ | China | Parallel RCT | 64 | Gastric cancer | Shenmen, sympathesis, stomach, large intestine, small intestine, Ashi point | Cowherb seeds | AA + antiemetics | Granisetron | (v) |
| Liu, 2017 [ | China | Parallel RCT | 70 | Cervical/endometrial/ovarian cancer | Stomach, liver, small intestine, Shenmen, endocrine | Cowherb seeds | AA | Ondansetron | (i); (iii); (iv); (vi) |
| Wang et al., 2017 [ | China | Parallel RCT | 52 | Bone cancer | Stomach, subcortex, ear center, Shenmen, spleen, sympathesis | Cowherb seeds | AA + antiemetics | Ondansetron | (ii); (iii); (iv) |
| Wu et al., 2018 [ | China | Parallel RCT | 86 | Lung cancer | M: stomach, cardia, subcortex A: liver, sympathesis | Cowherb seeds | AA + antiemetics | Ondansetron | (Iii) |
| Yang, 2018 [ | China | Parallel RCT | 67 | Breast cancer | M: stomach, Shenmen, subcortex, sympathesis; A: liver, spleen | Cowherb seeds | AA + antiemetics | Ondansetron | (i) (iii) (v) |
| Chen et al., 2019 [ | China | Parallel RCT | 89 | Colorectal cancer | Sympathesis, Shenmen, spleen, stomach | Cowherb seeds | AA + antiemetics | Azasetron + DXM | (v) |
| Nan et al., 2019 [ | China | Parallel RCT | 60 | Bone cancer | Stomach, ear center, sympathesis, spleen, Shenmen, subcortex | Cowherb seeds | AA + antiemetics | Ondansetron | (iii); (v) |
| Wen et al., 2019 [ | China | Parallel RCT | 100 | Various cancers | Shenmen, stomach, spleen | Cowherb seeds | AA + antiemetics | Azasetron | (v) |
| Wang et al., 2020 [ | China | Parallel RCT | 80 | Cervical cancer | Shenmen, sympathesis, stomach, subcortex, spleen | Cowherb seeds | AA + antiemetics | Ondansetron | (v) |
RCT: randomized controlled trial; Na: not available; M: main points; A: adjunct points; AA: auricular Acupressure; DXM: dexamethasone. Outcomes: (i) nausea relief efficiency; (ii) nausea frequency; (iii) vomiting relief efficiency; (iv) vomiting frequency; (v) overall efficiency of CINV; and (vi) incidence of adverse reactions.
Figure 1Flow diagram of study selection.
Figure 2Risk of bias summary.
Efficacy of auricular acupressure for nausea and vomiting outcomes.
| Outcome | Inclusion of studies | Sample size | Heterogeneity | Analysis model | RRa/SMDb (95% CI) | |
|---|---|---|---|---|---|---|
|
| ||||||
| Overall nausea relief efficiency | 5 | 358 | Fixed | 1.24a (1.09 to 1.43) |
| |
| Acute nausea relief efficiency | 4 | 238 | Fixed | 1.08a (0.95 to 1.22) | 0.23 | |
| Delayed nausea relief efficiency | 4 | 238 | Random | 1.30a (0.92 to 1.84) | 0.14 | |
|
| ||||||
|
| ||||||
| Acute nausea frequency | 2 | 128 | Random | −0.18 | 0.55 | |
| Delayed nausea frequency | 3 | 148 | Fixed | −0.68 | < | |
|
| ||||||
|
| ||||||
| Overall vomiting relief efficiency | 9 | 634 | Random | 1.14a (1.02 to 1.28) |
| |
| Acute vomiting relief efficiency | 5 | 323 | Fixed | 1.05a (0.93 to 1.18) | 0.44 | |
| Delayed vomiting relief efficiency | 5 | 323 | Fixed | 1.11a (1.01 to 1.21) |
| |
|
| ||||||
|
| ||||||
| Overall vomiting frequency | 2 | 89 | Random | −0.67b (−2.61 to 1.27) | 0.50 | |
| Acute vomiting frequency | 3 | 180 | Fixed | −0.18b (−0.47 to 0.12) | 0.23 | |
| Delayed vomiting frequency | 4 | 200 | Fixed | −0.91b (−1.22 to −0.61) | < | |
| Overall efficiency of CINV | 10 | 839 | Fixed | 1.31a (1.22 to 1.41) | < | |
|
| ||||||
|
| ||||||
| Overall incidence | 6 | 503 | Fixed | 0.62 (0.53 to 0.74) | < | |
| Constipation | 6 | 503 | Fixed | 0.61 (0.45 to 0.84) |
| |
| Diarrhoea | 2 | 196 | Fixed | 0.66 (0.45 to 0.98) |
| |
| Abdominal distension | 2 | 177 | I2 = 12%; | Fixed | 0.93 (0.71 to 1.24) | 0.63 |
| Headache | 2 | 135 | I2 = 0%; | Fixed | 0.43 (0.10 to 1.82) | 0.25 |
| Tiredness | 2 | 205 | Fixed | 0.39 (0.26 to 0.58) | < | |
aRR: risk ratio; bMD: mean difference; cimproved with sensitivity analysis; and dstatistically significant results are highlighted in bold.
Figure 3Overall nausea relief efficiency.
Figure 4Delayed nausea frequency.
Figure 5Delayed vomiting relief efficiency.
Figure 6Delayed vomiting frequency.
Figure 7Overall efficiency of CINV.
Figure 8Incidence of adverse reactions.